NeOnc Technologies Holdings has outlined a NeOnc trial plan targeting approximately 500 patients at 30 hospitals across three countries, a proposed expansion of its brain cancer research.
Key Takeaways
- The patient and hospital figures are targets, not completed enrollment.
- Earlier observations involving 25 patients were preliminary and do not establish treatment effectiveness.
NeOnc trial would expand clinical research
The proposed international study would move the company’s research into a larger clinical setting than the patient groups discussed in its early experience. NeOnc, which trades on Nasdaq under the ticker NTHI, described the plans during a television discussion reported on October 26, 2026.
The announcement did not specify a start date or identify the three countries or participating hospitals.
Delivery approach and early observations
NeOnc is investigating NEO100, an experimental treatment administered through the nose and designed to reach the brain while bypassing the blood-brain barrier. That barrier protects the brain but can also impede the delivery of potential therapies.
The company’s research also considers tumor characteristics, including IDH mutations, that may help identify patients who could respond to treatment.
In a December 2025 clinical update, NeOnc described significant radiographic remission in six of 25 patients across its combined clinical and compassionate-use experience. Those observations came from a small, nonrandomized population and cannot establish effectiveness or predict an individual patient’s outcome.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…